Health ❯ Healthcare ❯ Biotechnology

Pharmaceuticals

Cystic Fibrosis Treatments Clinical Trials Argenx SE AI in Healthcare Insmed Incorporated Cancer Treatment Antidotes Autoimmune Therapies Immunotherapy Drug Development Drug Approval Process Chronic Obstructive Pulmonary Disease Safety Regulations RNA-targeted Medicines Health Startups Antibody Therapy Biopharma Mergers Biotech Companies RNA Interference Rare Diseases Therapeutic Programs Regeneron ALS Treatments Regulatory Affairs Immunotherapy Companies B-cell Mediated Diseases Biopharmaceutical Companies

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

The all-cash $77-per-share tender offer is intended to add FB102, a first-in-class anti-CD122 antibody, to broaden argenx’s immunology pipeline beyond Vyvgart.

ClearBridge Adds ATI as SMID Growth Strategy Trails Benchmark

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Atara Investors Urged to Seek Lead Role in Securities Case Ahead of Deadline

Atara Faces Investor Class Action Over FDA Rejections of EBVALLO

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

Artisan Mid Cap Fund Tops Benchmark in Q3, Shifts Toward Defense and Industrials

PGIM Jennison’s Q2 Letter Details Health-Care Slide, Portfolio Shifts and Company Catalysts

Cytokinetics Hit With Securities Class Action Over Aficamten Timeline Disclosures

Biotech Veterans Launch Corsera Health to Develop a Once‑Yearly RNAi Heart Prevention Shot